<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> or spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) is a fatal, <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> disorder caused by a <z:chebi fb="1" ids="16040">cytosine</z:chebi>-<z:chebi fb="1" ids="16708">adenine</z:chebi>-<z:chebi fb="1" ids="16235">guanine</z:chebi> expansion in the coding region of the MJD1 gene </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi> interference has potential as a therapeutic approach but raises the issue of the role of <z:mp ids='MP_0002169'>wild-type</z:mp> ataxin-3 (WT ATX3) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> and of whether the expression of the <z:mp ids='MP_0002169'>wild-type</z:mp> protein must be maintained </plain></SENT>
<SENT sid="2" pm="."><plain>To address this issue, we both overexpressed and silenced WT ATX3 in a rat model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We showed that (i) overexpression of WT ATX3 did not protect against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> pathology, (ii) knockdown of WT ATX3 did not aggravate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> pathology and that (iii) non-allele-specific silencing of ataxin-3 strongly reduced neuropathology in a rat model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Our findings indicate that therapeutic strategies involving non-allele-specific silencing to treat <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients may be safe and effective </plain></SENT>
</text></document>